Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,077 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Clinical Recommendations Clear all
Terminated Phase 1Phase 2 Interventional

Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

NCT05427812
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
ISB 1442 SC injection escalating doses, ISB 1442 SC injection at RP2D
Drug
Lead sponsor
Ichnos Sciences SA
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Miami, Florida • Chicago, Illinois • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 20, 2026, 5:38 PM EDT
Recruiting Not applicable Interventional

Advanced Fibrosis Detection for MASLD in Primary Care

NCT07159386
View directory record Official record
Conditions
Metabolic Dysfunction-associated Steatotic Liver Disease
Interventions
EHR alert
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Terminated Phase 4 Interventional

Safety and Efficacy of Direct Blood Volume Measurement in the Treatment of Heart Failure

NCT01001312
View directory record Official record
Conditions
Heart Failure
Interventions
Daxor Blood Volume Analysis, Clinical volume status assessment
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
9
States / cities
Honolulu, Hawaii • Chicago, Illinois • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 20, 2026, 5:38 PM EDT
Recruiting Not applicable Interventional

Connect2Care: Prostate Cancer Education and Screenings for African American Men

NCT07055165
View directory record Official record
Conditions
Prostate Cancer, Health Behavior
Interventions
Prostate Cancer Genius App, US Prevention Taskforce App
Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
45 Years to 69 Years · Male only
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 20, 2026, 5:38 PM EDT
Recruiting Not applicable Interventional

The Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) ("JUPITER" TRIAL)

NCT05762302
View directory record Official record
Conditions
Lower Respiratory Tract Infection
Interventions
MeMed BV test
Diagnostic Test
Lead sponsor
MeMed Diagnostics Ltd.
Industry
Eligibility
18 Years to 99 Years
Enrollment
1,316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Jacksonville, Florida • Kansas City, Kansas • Brooklyn, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Completed No phase listed Observational

Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

NCT00897793
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
Interventions
venipuncture, radiation therapy
Procedure · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 1 Interventional

Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer

NCT03654547
View directory record Official record
Conditions
Advanced Solid Tumors, Triple Negative Breast Cancer
Interventions
TT-00420
Drug
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 20, 2026, 5:38 PM EDT
Recruiting Phase 1Phase 2 Interventional

Modulating Exercise Dosage to Improve Concussion Recovery

NCT05434130
View directory record Official record
Conditions
Concussion, Brain, Treatment, Aerobic Exercise, Inflammation, Depression, Anxiety
Interventions
High Dose Exercise
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
13 Years to 18 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Aurora, Colorado • Boston, Massachusetts • Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Recruiting Not applicable Interventional

Bilevel Positive Airway Pressure (BPAP) for Severe Asthma

NCT07582211
View directory record Official record
Conditions
Pediatric Asthma, Acute Asthma, BiPAP, Non-invasive Positive Pressure Ventilation
Interventions
Bilevel positive airway pressure ventilation
Device
Lead sponsor
Columbia University
Other
Eligibility
5 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
New York, New York • Columbus, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Not applicable Interventional

Improving Aspirin Use Among Adults at Risk for Cardiovascular Disease (CVD)

NCT00981032
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Pre-visit Summary, Clinical Decision Sharing Tool
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
45 Years to 70 Years
Enrollment
884 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Lewistown, Pennsylvania • Philipsburg, Pennsylvania • Scranton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2011 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 1 Interventional

A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors

NCT00880321
View directory record Official record
Conditions
Cancer
Interventions
GSK2118436, Midazolam
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Los Angeles, California • New York, New York • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 20, 2026, 5:38 PM EDT
Recruiting Not applicable Interventional

Building Social and Structural Connections for the Prevention of Opioid Use Disorder Among Youth Experiencing Homelessness

NCT06311838
View directory record Official record
Conditions
Opioid Use Disorder, Dual Diagnosis, Housing Problems, Mental Disorder in Adolescence, Risk Behavior, Homelessness
Interventions
Motivational Interviewing/Community Reinforcement Approach (MI/CRA), Strengths-Based Outreach and Advocacy (SBOA ), Services as Usual (SAU)
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
14 Years to 24 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Not applicable Interventional

A Pharmacokinetic/Pharmacodynamic Genetic Variation Treatment Algorithm Versus Treatment As Usual for Management Of Depression

NCT02189057
View directory record Official record
Conditions
Depression, Mood Disorder, Bipolar
Interventions
AssureRx GeneSight genotyping results, Treatment as usual
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Oct 20, 2026, 5:38 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

NCT01688492
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ipilimumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
3
States / cities
Evanston, Illinois • New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Recruiting Not applicable Interventional

BLOOM: Pragmatic Feasibility Trial

NCT07287332
View directory record Official record
Conditions
Sepsis, Infection
Interventions
Up-front individualized dosing algorithm, Usual Care
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Recruiting Phase 2 Interventional

24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC

NCT07043270
View directory record Official record
Conditions
Pancreas Adenocarcinoma
Interventions
Nab-paclitaxel + Gemcitabine, modified FOLFIRINOX (mFOLFIRINOX)
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Recruiting Not applicable Interventional

Emovi 3D Knee Assessment Device Intervention for Operational Readiness

NCT06517056
View directory record Official record
Conditions
Patellofemoral Pain, Patellofemoral Pain Syndrome
Interventions
Emovi Knee Kinesiography
Device
Lead sponsor
Womack Army Medical Center
Federal
Eligibility
18 Years to 50 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Honolulu, Hawaii • Fort Liberty, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 20, 2026, 5:38 PM EDT
Terminated Phase 1 Interventional Results available

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma

NCT02082977
View directory record Official record
Conditions
Cancer, Neoplasms
Interventions
GSK2816126
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 20, 2026, 5:38 PM EDT
Active, not recruiting Phase 4 Interventional

Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)

NCT04687020
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Viltolarsen
Drug
Lead sponsor
NS Pharma, Inc.
Industry
Eligibility
Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
4
States / cities
Sacramento, California • Chicago, Illinois • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Oct 20, 2026, 5:38 PM EDT
Recruiting Not applicable Interventional

Benchmark Evidence Led by Latin America: Trial of Intracranial Pressure - Pediatrics

NCT05566431
View directory record Official record
Conditions
Severe Traumatic Brain Injury
Interventions
ICP, CREVICE
Other
Lead sponsor
University of Washington
Other
Eligibility
1 Year to 12 Years
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 20, 2026, 5:38 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

NCT05607420
View directory record Official record
Conditions
B-cell Non-Hodgkin Lymphoma (B-NHL)
Interventions
UCART20x22, CLLS52
Biological
Lead sponsor
Cellectis S.A.
Industry
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Not applicable Interventional Results available

A Depression and Opioid Pragmatic Trial in Pharmacogenetics (Acute Pain Trial)

NCT05966129
View directory record Official record
Conditions
Acute Pain
Interventions
Pharmacogenetic testing, Clinical decisions support
Other
Lead sponsor
Duke University
Other
Eligibility
8 Years and older
Enrollment
1,602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
Wilmington, Delaware • Gainesville, Florida • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Recruiting Not applicable Interventional

Evaluation of a Novel Technology to Support Tailored Health Behavior Counseling in Rural Primary Care Clinics

NCT06397729
View directory record Official record
Conditions
Cardiovascular Diseases, Obesity
Interventions
Wait-List Control, PREVENT Tool
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis

NCT01154101
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo, SRT2104
Drug
Lead sponsor
Sirtris, a GSK Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
St Louis, Missouri • New York, New York • Portland, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 20, 2026, 5:38 PM EDT